DC2727: Breast Oncology – Best of 2026

Wednesday, November 4, 2026, 5:30 PM - 8:30 PM PT, Hotel, Seattle, WA

AMA PRA Category 1 Credits™ (2.00 hours), Non-Physician (2.00 hours)

This interactive, three-hour event will bring together regional healthcare professionals to discuss emerging clinical data, evolving standards of care, and practical applications of new therapies in both early-stage and metastatic breast cancer. Topics will include antibody-drug conjugates, recent approvals in the metastatic setting, and new developments in neoadjuvant and adjuvant treatment strategies. The program will feature faculty presentations, panel discussion, audience Q&A, and networking opportunities with colleagues from across the Puget Sound region.

Contact

Register

1. Describe the role of antibody drug conjugates in the management of metastatic triple negative breast cancer and review updated treatment guidelines based on new treatment approvals.
2. Explain the role of antibody drug conjugates in the management of metastatic HER2+ breast cancer including risks and benefits of ADC use in the first-line setting.
3. Discuss the role of antibody drug conjugates in the management of early-stage HER2+ breast cancer and review new treatment approvals in the adjuvant and neoadjuvant setting.
4. Address implicit bias in the management of breast cancer and examine disparities affecting patient outcomes.

Contact

Register

In support of improving patient care, the University of Washington School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Washington School of Medicine designates this Live Activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

University of Washington School of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited activity, including faculty, planners, reviewers or others in control of content are required to disclose all relevant financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the start of the activity. All those in control of content have no financial relationships to disclose, unless otherwise listed.

Wednesday, November 4, 2026